These HIF2α antagonists inhibit HIF2α transcriptional activity by inhibiting the protein–protein interaction between HIF2α and HIF1β, resulting in intense anti-tumor activity in vivo and in vitro (Wigerup et al, 2016). The gene discussed is EPAS1; the disease is neoplasm.